CARGO Therapeutics (CRGX) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• CARGO Therapeutics is set to announce its Q2 2025 earnings results on August 11, with analysts predicting an earnings per share of ($0.42).
• The stock has seen a recent trading price of $4.48, with a market capitalization of $206.34 million and a 12-month trading range of $3.00 to $25.45.
• Invesco Ltd. has significantly increased its stake in CARGO Therapeutics by 146.9%, holding approximately 0.06% of the company, indicating strong institutional interest.

CARGO Therapeutics (NASDAQ:CRGX - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.42) per share for the quarter.

CARGO Therapeutics Trading Up 0.2%

NASDAQ CRGX traded up $0.01 during trading hours on Friday, reaching $4.49. 1,247,466 shares of the company's stock were exchanged, compared to its average volume of 1,188,569. The firm has a fifty day moving average of $4.45 and a 200-day moving average of $4.58. CARGO Therapeutics has a one year low of $3.00 and a one year high of $25.45. The stock has a market cap of $207.03 million, a PE ratio of -0.97 and a beta of 0.30.

Hedge Funds Weigh In On CARGO Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its stake in CARGO Therapeutics by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 876,245 shares of the company's stock valued at $3,611,000 after acquiring an additional 16,392 shares in the last quarter. Invesco Ltd. grew its position in CARGO Therapeutics by 146.9% in the first quarter. Invesco Ltd. now owns 28,266 shares of the company's stock valued at $115,000 after purchasing an additional 16,818 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new stake in CARGO Therapeutics in the 1st quarter valued at $217,000. 93.16% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Jefferies Financial Group increased their price objective on CARGO Therapeutics from $3.70 to $5.00 and gave the company a "hold" rating in a research report on Tuesday, July 8th. One investment analyst has rated the stock with a sell rating and six have assigned a hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $15.40.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.